Soumen Paul serves as a Study Director at BIOQUAL, Inc., where he leads the Imaging Unit with a focus on in-vivo molecular imaging using Positron Emission Tomography (PET). His expertise lies in investigating receptor expression, occupancy, and the biochemistry of living organs, which is crucial...
Soumen Paul serves as a Study Director at BIOQUAL, Inc., where he leads the Imaging Unit with a focus on in-vivo molecular imaging using Positron Emission Tomography (PET). His expertise lies in investigating receptor expression, occupancy, and the biochemistry of living organs, which is crucial for advancing our understanding of various physiological and pathological processes. By employing sophisticated PET pharmacokinetic modeling, Soumen quantifies the kinetics of radiotracers within physiological systems, enabling precise insights into biological mechanisms.
In his role, Soumen is responsible for developing comprehensive imaging protocols and preparing final reports and publications that contribute to the scientific community's knowledge base. He oversees the procurement of radioligands, ensuring the optimal performance of PET-CT systems, which is vital for achieving accurate imaging results. His collaborative approach involves regular interactions with technical teams to ensure that studies are executed efficiently and meet the highest standards of scientific rigor.
Soumen's strong background in in-vitro techniques complements his in-vivo work, allowing him to bridge the gap between laboratory research and clinical applications. His proficiency in immunohistochemistry, Western blotting, PCR, and ELISA further enhances his ability to conduct thorough medical research. As he continues to develop new procedures, standard operating protocols (SOPs), and innovative study designs, Soumen Paul remains at the forefront of molecular imaging research, driving advancements that have the potential to transform diagnostic and therapeutic strategies in medicine.
